Rates of Invasive Pneumococcal Disease in Adults With HIV in the Era of 13-Valent Pneumococcal Conjugate Vaccine, 2008-2018

September 29 - October 3, 2021; Virtual
Active surveillance demonstrates that introduction of PCV13 led to declines in IPD in people with and without HIV and suggests benefits of newly approved higher valency PCVs.
Format: Microsoft PowerPoint (.ppt)
File Size: 419 KB
Released: October 7, 2021

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Hear experts discuss their approach to treating patients with infections caused by XDROs, from Clinical Care Options (CCO)

Yohei Doi Headshot Yohei Doi, MD, PhD
Program Director
Emily Heil, PharmD, MS, BCIDP, AAHIVP
Program Director
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: February 3, 2023 Expired: February 2, 2024

Dr Helen Chu shares how the COVID-19 pandemic has influenced RSV diagnostic and prevention efforts, from Clinical Care Options (CCO)

Helen Y. Chu, MD, MPH Released: January 31, 2023

Learn from Dr Zhuxin Mao about emerging data on quantifying quality of life of older adults with RSV, from Clinical Care Options (CCO)

person default Zhuxin Mao, PhD Released: January 30, 2023

Dr Kenric Ware discusses how technology and social media can impact PrEP adherence and persistence, from Clinical Care Options (CCO)

person default Kenric Ware, PharmD, AAHIVP Released: January 23, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings